Shailender Bhatia, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    NantKwest
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    05/31/2021
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Nektar Therapeutics
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    02/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Novartis
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    04/30/2022
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Trisalus Life Sciences
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Xencor
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron/Sanofi
    Topic:
    Advisory board
    Date added:
    03/09/2023
    Date updated:
    02/13/2024
    Relationship end date:
    06/15/2021

Pages

Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology